Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service.

Borges AP, Guidoni CM, Freitas Od, Pereira LR.

Arq Bras Endocrinol Metabol. 2011 Dec;55(9):686-91.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

A comparison of costs for four oral antidiabetic regimens within a managed care population.

Stockl K, Vanderplas AM, Nicklasson L.

Manag Care Interface. 2003 Jul;16(7):31-6.

PMID:
12908215
4.

Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.

Gundgaard J, Christensen TE, Thomsen TL.

Prim Care Diabetes. 2010 Oct;4(3):165-72. doi: 10.1016/j.pcd.2010.04.004. Epub 2010 May 10.

PMID:
20452847
5.

Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST.

Pharmacoeconomics. 2003;21(11):819-37.

PMID:
12859222
6.
7.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
8.

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.

Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

Postgrad Med. 2012 Jan;124(1):124-32. doi: 10.3810/pgm.2012.01.2525.

PMID:
22314122
9.
10.

A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.

Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B.

Clin Ther. 2009 Mar;31(3):623-31. doi: 10.1016/j.clinthera.2009.03.005.

PMID:
19393853
12.
14.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
15.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
16.

[Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study].

Costi M, Smith H, Reviriego J, Castell C, Goday A, Dilla T.

Endocrinol Nutr. 2011 Jun-Jul;58(6):274-82. doi: 10.1016/j.endonu.2011.03.004. Spanish.

PMID:
21641287
17.

Willingness to pay for inhaled insulin: a contingent valuation approach.

Sadri H, MacKeigan LD, Leiter LA, Einarson TR.

Pharmacoeconomics. 2005;23(12):1215-27.

PMID:
16336016
18.

Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus.

Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC.

Am J Health Syst Pharm. 2001 Jan 15;58(2):151-7.

PMID:
11202539
19.

[Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].

Schiel R, Müller UA, Stein G.

Med Klin (Munich). 2005 Aug 15;100(8):453-61. German.

PMID:
16096726
20.

Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes.

Brown RR.

Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S24-7. No abstract available.

PMID:
9872692

Supplemental Content

Support Center